The trial by Torres et al. (8) demonstrated that methylprednisolone reduced treatment failure in patients with severe pneumonia and elevated C-reactive protein (CRP >150 mg/L), suggesting benefit in those with a heightened inflammatory response. Here, CRP is linked to pneumonia.